Vir Biotechnology (VIR) Change in Receivables (2021 - 2024)

Vir Biotechnology has disclosed Change in Receivables across 4 years of filings, most recently posting $8.7 million for Q4 2024.

• Change in Receivables for Q4 2024 came in at $8.7 million, up 142.57% year-over-year; the trailing twelve-month figure through Dec 2024 was $6.5 million (up 1052.74% YoY), and the FY2024 annual result was $6.5 million, up 1052.74% from the prior year.
• Change in Receivables came in at $8.7 million for Q4 2024 at Vir Biotechnology, up from $54000.0 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $680.1 million in Q4 2021 to a low of -$883.8 million in Q2 2022.
• The 4-year median for Change in Receivables is $54000.0 (2024), against an average of $778384.6.
• Peak annual rise in Change in Receivables reached 142.57% in 2024, while the deepest fall reached 183.65% in 2024.
• Vir Biotechnology's Change in Receivables stood at $680.1 million in 2021, then slumped by 140.9% to -$278.2 million in 2022, then surged by 101.3% to $3.6 million in 2023, then soared by 142.57% to $8.7 million in 2024.
• The last three Change in Receivables figures came in at $8.7 million (Q4 2024), $54000.0 (Q3 2024), and -$2.7 million (Q2 2024), per Business Quant data.